EGON-ZEHNDER
21.6.2022 16:47:03 CEST | Business Wire | Press release
Michael Ensser has been elected Chair of Egon Zehnder by the partnership of the world’s leadership advisory firm. He assumes the role on Nov. 1, 2022, succeeding Jill Ader, who has chaired the Firm since 2018 and will transition to an advisory role.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220621005820/en/
“As our next chair, Michael embodies values-driven leadership, putting humanity and empathy at the core of all he does, which is exactly the type of leader we need to continue the Firm’s tremendous growth, expanding the reach of our leadership advisory capabilities as organizations face increased complexity and transformative challenges,” said Ader.
Over his 25 years at Egon Zehnder, Ensser has played key roles, including leading the German market, the second largest for Egon Zehnder, where he pioneered Leadership Advisory services, as well as leading the Switzerland market. Before that, Ensser led the Berlin Office, which under his leadership grew to one of the biggest offices in the Firm. Ensser currently serves on Egon Zehnder’s board, co-chairing its People Committee and is also chair of Germany’s Board Academy, co-created with McKinsey and KPMG, which prepares executives for non-executive board positions. He also helped to launch Egon Zehnder’s second global knowledge center in Budapest.
Ensser was elected by Egon Zehnder’s partnership, where every partner has an equal vote in the selection of the chair, a legacy from the Firm’s eponymous founder, who believed strongly in true partnership and good governance. Elections take place every three years, and chairs can serve for a maximum of two terms.
“I am honored and grateful to our partners for placing their trust in me to lead our Firm in this next chapter,” said Ensser. “Building on our Firm’s values, we will continue to grow our Firm’s leadership advisory capabilities to better serve our clients, deliver on our commitments to diversity, equity, and inclusion, and increase our focus on sustainability.”
Ensser’s election is part of a planned succession. The chair must be a partner in the Firm, and the partnership has a tenure limit of age 62. Following those guidelines, Ader will retire from the partnership of Egon Zehnder later this year, and she will transition to a senior advisor role, focusing on both client work and helping colleagues to flourish. “Jill has been nothing short of outstanding as our chair, helping to crystallize our values, increase our diversity, equity and inclusion efforts and amplify our role as leadership advisors and coaches,” said Edilson Camara, Chief Executive Officer of Egon Zehnder. “We are grateful that Jill will be returning to client-focused work, as our world needs great leaders more than ever before.”
About Egon Zehnder
Egon Zehnder is the world’s preeminent leadership advisory firm, inspiring leaders to navigate complex questions with human answers. We help organizations get to the heart of their leadership challenges and offer honest feedback and insights to help leaders realize their true being and purpose. Our 560 consultants across 63 offices and 36 countries are former industry and functional leaders who collaborate seamlessly across geographies, industries, and functions to deliver the full power of the Firm to every client, every time.
We believe that together we can transform people, organizations, and the world through leadership.
For more information, visit egonzehnder.com and follow us on LinkedIn and Twitter .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220621005820/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
TVS Motor Company Appoints Peyman Kargar as Director and Chief Executive Officer28.8.2026 09:31:00 CEST | Press release
Peyman Kargar appointed Director and Chief Executive Officer of TVS Motor Company, effective January 27, 2027 K. N. Radhakrishnan to continue as Director and Chief Executive Officer until then and subsequently will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027 Appointment supports TVS Motor Company's next phase of growth and innovation TVS Motor Company, part of TVS VENU and a leading global manufacturer of two and three-wheelers, today announced the appointment of Peyman Kargar as Director and Chief Executive Officer, effective January 27, 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827012301/en/ Peyman Kargar Peyman will succeed K. N. Radhakrishnan, who will continue in his role until then to ensure a seamless transition. Following the transition, Radhakrishnan will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027. He has been a
Philips and Imricor Launch Cardiac Interventional MR Lab Solution, Expanding Longstanding Collaboration27.8.2026 21:27:00 CEST | Press release
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Imricor Medical Systems (ASX: IMR), a pioneer and world-leading developer of MR-compatible products for interventional MR procedures, today announced a new Interventional MR (iMR) lab solution for Philips 1.5T MR. The first commercially available configuration* combines Philips’ 1.5T MRI platform and Imricor's portfolio of iMR systems and consumables, enabling an MR-guided workflow for cardiac intervention, without compromising on MR field strength. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827693715/en/ Meeting the need for greater tissue insight during cardiac intervention Cardiac arrhythmias affect millions of people worldwide, and catheter ablation is an established and increasingly utilized treatment for many complex cardiac arrhythmias. Yet today, these procedures continue to rely primarily on X-ray fluoroscopy, which provides only
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
